Slide 1: First Quarter 2026 Financial Results
First Quarter 2026 Financial Results May 11, 2026
Slide 2: Disclaimer
Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. In addition, unless otherwise indicated, references to the “Company,” “Cer
Slide 3: Financial Highlights First Quarter 2026
Financial Highlights First Quarter 2026 REVENUE NET INCOME ADJ. EBITDA(1) DILUTED EPS ADJUSTED DILUTED EPS(2) $106.9M ($8.8M) $31.7M ($0.06) $0.09 1% YoY change PY $4.7M (9%) YoY change PY $0.03 PY $0.14 (1) See Appendix for reconciliation of net income (loss) to adjusted EBITDA (2) See Appendix for
Slide 4: 1Q 2026 Results - Revenue
1Q 2026 Results - Revenue GAAP Reported Revenue ($Millions) 106.0 106.9 59.6 57.2 46.4 49.7 1Q 2025 1Q 2026 Software Services Certara reported 1% revenue growth during the first quarter 4
Slide 5: 1Q 2026 and TTM Results - Net Bookings
1Q 2026 and TTM Results - Net Bookings 1Q Reported Net Bookings TTM Reported Net Bookings ($Millions) ($Millions) 118.2 115.3 457.7 479.2 280.5 286.9 77.4 66.6 40.8 48.7 177.2 192.3 1Q 2025 1Q 2026 1Q 2025 1Q 2026 Software Services Software Services Trailing twelve-month bookings grew +5% vs. the pr
Slide 6: Historical TTM Book to Bill
Historical TTM Book to Bill ($Millions) 1.16x 1.13x 1.15x 1.14x $485 1.16x $465 $445 $425 $405 $385 $365 $345 $325 $305 $285 $265 482.1 $245 457.7 470.8 471.4 479.2 $225 405.8 415.6 418.8 419.8 $205 394.5 $185 $165 $145 $125 $105 $85 $65 $45 $25 1Q 2025 2Q 2025 3Q 2025 4Q 2025 1Q 2026 TTM Bookings T
Slide 7: Historical Software Net Retention Rate (NRR)
Historical Software Net Retention Rate (NRR)(1) 115.0% 114.1% 110.0% 108.0% 107.6% 107.6% 107.2% 106.1% 105.5% 105.0% 103.9% 102.4% 100.0% 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1 NRR(1) provides insight into growth and retention among existing software customers (1) O
Slide 8: 1Q 2026 Results – Adjusted EBITDA
1Q 2026 Results – Adjusted EBITDA 1Q Adjusted EBITDA(1) ($Millions) 34.8 31.7 1Q 2025 1Q 2026 Adjusted EBITDA 33% 30% Margin(1) 1Q26 Adjusted EBITDA declined (9%) vs. the prior year period 8 (1) See Appendix for a reconciliation net income (loss) to adjusted EBITDA
Slide 9: 1Q26 Business Updates
1Q26 Business Updates Key Takeaways from First Quarter 2026: Closed Divestiture of 1Q Performance In-Line AI Innovation and Regulatory & Medical Writing with Plan Leadership • Sold business to Veristat for a • Total revenue was in-line with • Appointed Dr. Chris Bouton as our consideration of up to
Slide 10: 1Q26 Bookings YoY Trends – Pharma/Biotech Customers
1Q26 Bookings YoY Trends – Pharma/Biotech Customers Tier1 Software Bookings | +20% y/y Services Bookings | (14%) y/y I Solid growth driven by expansion among Decline driven by execution and go-to- existing customers market challenges Strongest area of growth driven by further II Decline in regulator
Slide 11: 2026 Outlook
2026 Outlook Updating FY 2026 guidance Key Assumptions 2026 Guidance REVENUE ADJUSTED ADJUSTED EBITDA MARGIN (1) DILUTED EPS(1) Regulatory and Medical Writing $395-$405M 30-32% $0.35-$0.41 revenue of ~$18M Ex-regulatory revenue growth of 0-4% Fully diluted shares expected to be in the range of 157-1
Slide 12: Appendix
Appendix CERTARAQ
Slide 13: Regulatory and Medical Writing – Supplemental Information
Regulatory and Medical Writing – Supplemental Information On April 22nd, 2026, Certara announced it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction closed on May 8th, 2026. Historical R
Slide 14: Reconciliation of Net Income (Loss) to Adjusted EBITDA
Reconciliation of Net Income (Loss) to Adjusted EBITDA For the three months ended March 31, (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) 2026 2025 Net income attributable to common stockholders of Certara, Inc. (8,763) 4,743 Reconciliation to Adjusted EBITDA: Interest expense(a) 4,941 4,806 Inter
Slide 15: Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)
Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss) For the three months ended March 31, (IN THOUSANDS, EXCEPT PER SHARE AND SHARE DATA) 2026 2025 Net income attributable to common stockholders of Certara, Inc. (8,763) 4,743 Reconciliation to Adjusted Net Income: Currency (gain) loss(a
Slide 16: Reconciliation of Diluted EPS to Adjusted Diluted EPS
Reconciliation of Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share THREE MONTHS ENDED MARCH 31, 2026 2025 Diluted earnings per share(a) $ (0.06) $ 0.03 Currency (gain) loss(a) - - Equity-based compensation expense(b) 0.05 0.04 Amortization of acquisition-related intangible assets(c)
Slide 17: Notes to Reconciliations
Notes to Reconciliations a) Represents a measure determined under GAAP. b) Represents expense related to equity-based compensation. Equity-based compensation has been, and will continue to be for the foreseeable future, a recurring expense in our business and an important part of our compensation st
Slide 18: Accelerating Medicines, Together
Accelerating Medicines, Together